# Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients

> **NCT02651376** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing 302 Hospital** · enrollment: 20 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Immunodeficiency

## Interventions

- **COMBINATION_PRODUCT:** Conventional plus AAIT

## Key facts

- **NCT ID:** NCT02651376
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-04
- **Final completion:** 2017-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02651376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02651376, "Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02651376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*